Skip to main content
Assets
Regeneron Pharmaceuticals logo
REGN.NASDAQ
Regeneron Pharmaceuticals
Health Care · Biotechnology

Biotechnology company inventing life-transforming medicines for serious diseases including cancer and cardiovascular conditions.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Regeneron Pharmaceuticals.

Historical AI Opinions

Regeneron Pharmaceuticals, Inc. (REGN.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+70.6%

Includes 0.35% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.367.98626.49884.991.14K1.4KNov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$825+5.2%Not Generated this time
$855+9.0%Not Generated this time
$895+14.1%Not Generated this time
$936+19.2%Not Generated this time
$981+25.0%Not Generated this time
$1,045+33.2%Not Generated this time
$1,106+40.9%Not Generated this time
$1,176+49.8%Not Generated this time
$1,246+58.8%Not Generated this time
$1,316+67.7%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Regeneron executes a 'soft landing' for its retina franchise, where Eylea HD captures sufficient market share to stabilize revenues despite biosimilar erosion of the legacy product. Dupixent remains the primary growth engine, with the COPD indication adding significant reliable revenue, supporting double-digit earnings growth. The pipeline offers moderate success, particularly in oncology adjacencies (Libtayo combos), while the company maintains a fortress balance sheet. The stock compounds steadily, reflecting a premium valuation for high-quality execution and confirmed growth in immunology, even as the retinal market matures. This thesis assumes a balanced outcome between innovation wins and competitive headwinds.

2. Scenarios & Signals

2.1. Bull Case

In this scenario, Regeneron's Dupixent exceeds expectations with rapid uptake in the newly approved COPD indication, becoming a multi-blockbuster driver that offsets any Eylea declines. Eylea HD successfully converts over 70% of the legacy Eylea patient base, effectively fencing off biosimilar competition and neutralizing Roche's Vabysmo threat through superior durability data and the launch of a pre-filled syringe. The oncology pipeline delivers a major win with fianlimab (LAG-3) demonstrating best-in-class efficacy in melanoma and lung cancer, unlocking a third major revenue pillar. Additionally, early-stage genetic medicine partnerships with Intellia yield a functional cure candidate entering pivotal trials. This multiple expansion drives the stock significantly higher as Regeneron is repriced as a high-growth innovator rather than a maturing biotech.

2.2. Bear Case

Here, the Eylea franchise deteriorates faster than anticipated due to aggressive biosimilar pricing and Vabysmo capturing significant market share, with Eylea HD failing to gain dominant formulary status. The delay in the Eylea HD pre-filled syringe (PFS) allows competitors to entrench themselves. Dupixent growth in COPD disappoints due to payer friction or competitive pressures from other biologics like TEZSPIRE. The oncology pipeline faces setbacks, with key assets failing in Phase 3 or showing undifferentiated safety profiles. The combined pressure of the Inflation Reduction Act (IRA) targeting Eylea/Dupixent pricing and a lack of new blockbuster launches compresses the P/E multiple, causing the stock to stagnate or decline as it transitions to a low-growth value trap.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 2,680Thinking Tokens: 1,735Response Tokens: 7,541Total Tokens: 11,956
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.